Rein 3D PRINT PERSONALIZE
Launched by UNIVERSITY HOSPITAL, BORDEAUX · Apr 17, 2024
Trial Information
Current as of August 28, 2025
Recruiting
Keywords
ClinConnect Summary
The Rein 3D PRINT PERSONALIZE clinical trial is studying the use of personalized 3D printed models of patients' tumoral kidneys compared to standard, generic models. This trial aims to see how these different models affect the information patients receive and their overall experience before and after a surgery called laparoscopic robotic-assisted partial nephrectomy, which helps remove tumors while preserving as much healthy kidney tissue as possible. The main way researchers will gather information is through interviews with patients and their caregivers.
To be eligible for this trial, participants must be adults (18 years or older) who are scheduled for the surgery mentioned above and must agree to join the study. They should also have a good quality CT scan available for creating the 3D models. Patients with certain conditions, like metastatic cancer or previous kidney cancers, or those who face language barriers, will not be included. Participants can expect to share their experiences through interviews, which will help researchers understand how helpful these personalized models are in improving patient care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients:
- • Adult patients (≥ 18 years of age)
- • Scheduled for surgical management by laparoscopic robotic-assisted partial nephrectomy (1st management for a unilateral or bilateral kidney tumor)
- • Expressed consent for integration in the UroCCR database
- • Expressed consent for participation in the Rein-3D Personalize study
- • Patients affiliated or benefiting from social security system
- Professionals:
- • Professionals working with patients treated in the Urology, Andrology and Renal Transplant - Department of the Bordeaux University Hospital for at least two months prior to the implementation of 3D models
- • Free, informed and signed consent
- Exclusion Criteria:
- • Patients
- • Metastatic at inclusion
- • Previous renal cancer(s)
- • Single kidney at time of inclusion
- • No preoperative CT scan, or poor-quality CT scan unable to provide reliable 3D modeling
- • Person under legal protection (safeguard of justice, guardianship or curatorship)
- • Difficulty understanding and expressing oneself in French
- • Professionals
- • Professionals on internship lasting less than 6 months
- • Professionals with no contact with patients
About University Hospital, Bordeaux
The University Hospital of Bordeaux is a leading academic medical center dedicated to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the institution integrates cutting-edge scientific inquiry with patient care, fostering an environment that encourages collaboration among multidisciplinary teams. With a commitment to improving treatment outcomes and enhancing patient safety, the University Hospital of Bordeaux plays a pivotal role in the development of new therapies and medical technologies, contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, , France
Patients applied
Trial Officials
Gaëlle MARGUE, Docteur
Principal Investigator
University Hospital, Bordeaux
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported